Connor, Clark & Lunn Investment Management (CC&L)
RLAY icon

Connor, Clark & Lunn Investment Management (CC&L)’s Relay Therapeutics RLAY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18M Buy
961,702
+124,664
+15% +$1.81M 0.03% 387
2026
Q1 		$8.33M Buy
837,038
+447,475
+115% +$4M 0.02% 527
2025
Q4 		$3.3M Buy
+389,563
New +$2.78M 0.01% 785
2024
Q2 		– Sell
-43,382
Closed -$360K – 1645
2024
Q1 		$360K Sell
43,382
-22,954
-35% -$224K ﹤0.01% 1205
2023
Q4 		$730K Buy
66,336
+27,134
+69% +$229K ﹤0.01% 952
2023
Q3 		$330K Buy
+39,202
New +$422K ﹤0.01% 1120

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RLAY Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Relay Therapeutics (RLAY) stake by 15% in Q2 2026, buying an estimated $1.81M and bringing the position to 961,702 shares worth $18M. The position accounts for 0.03% of the portfolio, ranked #387.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RLAY in Q3 2023 and has held it in 6 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 961,702 shares of Relay Therapeutics worth $18M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 124,664 Relay Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Relay Therapeutics made up 0.03% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #387 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Relay Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.